CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro

John P. Moore; Guy Simpson; Jane A. Mckeating; Steven J. Burakoff; Stuart L. Schreiber; Robin A. Weiss

doi:10.1016/0042-6822(92)90508-M

CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro

John P. Moore, Guy Simpson, Jane A. Mckeating, Steven J. Burakoff, Stuart L. Schreiber, Robin A. Weiss

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gpl20 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gpl 20 binding to CD4 in vitro (Finberg et al, Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gpl20-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneveloped viruses was unaffected or only slightly reduced.

Original language	English
Pages (from-to)	537-544
Number of pages	8
Journal	Virology
Volume	188
Issue number	2
DOIs	https://doi.org/10.1016/0042-6822(92)90508-M
State	Published - Jun 1992
Externally published	Yes

Access to Document

10.1016/0042-6822(92)90508-M

Cite this

@article{888ae793d47847bdbfecae4c5d52670a,

title = "CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro",

abstract = "The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gpl20 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gpl 20 binding to CD4 in vitro (Finberg et al, Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gpl20-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneveloped viruses was unaffected or only slightly reduced.",

author = "Moore, {John P.} and Guy Simpson and Mckeating, {Jane A.} and Burakoff, {Steven J.} and Schreiber, {Stuart L.} and Weiss, {Robin A.}",

note = "Funding Information: We thank D. B. Mitchell for preparing the samples of CPFs used in these investigations. We appreciate the advice of YasuhiroTakeuchi on SSAV pseudotype assays. We are grateful to Mark Marsh (Chester Beatty Labs) for anti-sCD4 antiserum CBL-34. Ray Sweet (Smith Kline Beecham) for sCD4, and Harvey Holmes of the ADP reagent programme for many reagents. This work was funded by the AIDS Directed Programme (ADP) of the UK Medical Research Council and by the Cancer Research Campaign.",

year = "1992",

month = jun,

doi = "10.1016/0042-6822(92)90508-M",

language = "English",

volume = "188",

pages = "537--544",

journal = "Virology",

issn = "0042-6822",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro

AU - Moore, John P.

AU - Simpson, Guy

AU - Mckeating, Jane A.

AU - Burakoff, Steven J.

AU - Schreiber, Stuart L.

AU - Weiss, Robin A.

N1 - Funding Information: We thank D. B. Mitchell for preparing the samples of CPFs used in these investigations. We appreciate the advice of YasuhiroTakeuchi on SSAV pseudotype assays. We are grateful to Mark Marsh (Chester Beatty Labs) for anti-sCD4 antiserum CBL-34. Ray Sweet (Smith Kline Beecham) for sCD4, and Harvey Holmes of the ADP reagent programme for many reagents. This work was funded by the AIDS Directed Programme (ADP) of the UK Medical Research Council and by the Cancer Research Campaign.

PY - 1992/6

Y1 - 1992/6

N2 - The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gpl20 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gpl 20 binding to CD4 in vitro (Finberg et al, Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gpl20-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneveloped viruses was unaffected or only slightly reduced.

AB - The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gpl20 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gpl 20 binding to CD4 in vitro (Finberg et al, Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gpl20-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneveloped viruses was unaffected or only slightly reduced.

UR - http://www.scopus.com/inward/record.url?scp=0026655103&partnerID=8YFLogxK

U2 - 10.1016/0042-6822(92)90508-M

DO - 10.1016/0042-6822(92)90508-M

M3 - Article

C2 - 1316672

AN - SCOPUS:0026655103

SN - 0042-6822

VL - 188

SP - 537

EP - 544

JO - Virology

JF - Virology

IS - 2

ER -

CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro

Abstract

Access to Document

Fingerprint

Cite this